Trial-Results center  
Clinical trial results database Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

diabetes - anti hypertensive agent - type1 and 2 diabetic patients with hypertension

hypertension - anti hypertensive agent - diabetic patients


Related trials

ACCOMPLISH (diabetic subgroup), 2010 - benazepril + amlodipine vs benazepril + hydrochlorothiazide

ACCORD blood pressure, 2010 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

AVOID, 2008 - aliskiren vs placebo

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril vs chlorthalidone

LIFE (diabetic subgroup), 2002 - losartan vs atenolol

ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002 - amlodipine vs chlorthalidone

IPDM, 2001 - irbesartan vs placebo

IDNT amlodipine, 2001 - amlodipine vs placebo

RENAAL, 2001 - losartan vs placebo

IDNT irbesartan, 2001 - Irbesartan vs placebo

IDNT (irbesartan vs amlodipine), 2001 - Irbesartan vs amlodipine

STOP-2 CCB (diabetic subgroup), 2000 - calcium-channel blocker vs diuretic or beta-blocker

INSIGHT (diabetic subgroup), 2000 - Nifedipine vs coamilozide

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

NORDIL (diabetic subgroup), 2000 - Diltiazem vs diuretic or beta-blocker

STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor vs CCB

HOPE (diabetic subgroup), 2000 - ACE inhibitor vs placebo

STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor vs diuretic or beta-blocker

CAPP (diabetic subgroup), 1999 - captopril vs diuretic or beta-blocker

Syst-Eur (diabetic subgroup), 1999 - nitrendipine vs placebo

ABCD, 1998 - nisoldipine vs enalapril

UKPDS 38, 1998 - captopril or atenolol vs control

UKPDS 39, 1998 - captopril vs atenolol

FACET, 1997 - amlodipine vs fosinopril



See also:

  • All diabetes clinical trials
  • All hypertension clinical trials
  • All clinical trials of anti hypertensive agent
  • All clinical trials of calcium-channel blocker
    		•  

    STOP-2 CCB (diabetic subgroup) study, 2000

    Facebook    pdf : calcium-channel blocker - anti hypertensive agent for hypertension

    Treatments

    Studied treatment Calcium-channel blocker
    felodipine 2�5 mg or isradipine 2�5 mg daily. if the target blood pressure (<160/95 mm Hg) had not been reached at the 2-month visit or later patients were given any of the b-blockers in the doses listed
    Control treatment diuretic or beta-blocker
    atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or fixed-ratio hydrochlorothiazide 25 mg plus amiloride 2�5 mg daily. Patients on beta-blockers were given hydrochlorothiazide 25 mg plus amiloride 2�5 mg as additional treatment if the target blood pressure (<160/95 mm Hg) had not been reached at the 2-month visit or later. Patients who had started on diuretic treatment were given any of the b-blockers in the doses listed

    Patients

    Patients diabetic (subgroup) elderly patients aged 70-84 years
    Inclusion criteria hypertension (blood pressure >=180 mm Hg systolic, >=105 mmHg diastolic, or both); aged 70�84 years; isolated systolic hypertension could be included
    Remarks Of all 6614 patients included in the trial, 719 had diabetes
    Baseline characteristics
    Glycosylated hemoglobin 7.6% 
    BP (systolic/diastolic) 195/96 mmHg 
    Female (%) 60% 
    Age 75.8 y 
    subgroup yes 
    hypertension (%) 100% 

    Method and design

    Randomized effectives 231 / 253 (studied vs. control)
    Design Parallel groups
    Blinding open with blind assessment
    Follow-up duration 5.03y
    Number of centre 312
    Geographic area Sweden
    Primary endpoint renal death
    Remarks


    Results



    Endpoints and data reported in the trial's publication(s)

    Endpoint Events (%) Relative Risk 95% CI
    Studied treat. Control treat.
    Cardiovascular mortality 33 / 231 (14,3%) 45 / 253 (17,8%) 0,80 [0,53;1,21]
    Fatal myocardial infarction 7 / 231 (3,0%) 9 / 253 (3,6%) 0,85 [0,32;2,25]
    Fatal stroke 8 / 231 (3,5%) 9 / 253 (3,6%) 0,97 [0,38;2,48]
    Sudden death 11 / 231 (4,8%) 12 / 253 (4,7%) 1,00 [0,45;2,23]
    Other cardiovascular mortality 7 / 231 (3,0%) 15 / 253 (5,9%) 0,51 [0,21;1,23]
    All myocardial infarction 32 / 231 (13,9%) 26 / 253 (10,3%) 1,35 [0,83;2,19]
    All stroke 29 / 231 (12,6%) 39 / 253 (15,4%) 0,81 [0,52;1,27]
    All major cardiovascular events 69 / 231 (29,9%) 82 / 253 (32,4%) 0,92 [0,71;1,20]
    Total mortality 50 / 231 (21,6%) 67 / 253 (26,5%) 0,82 [0,59;1,13]
    Atrial fibrillation 24 / 231 (10,4%) 26 / 253 (10,3%) 1,01 [0,60;1,71]
    Congestive heart failure 24 / 231 (10,4%) 29 / 253 (11,5%) 0,91 [0,54;1,51]

    Endpoints used by the meta-analysis and data retained for this trial

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    cardiovascular event (fatal and non fatal)

    NA / 719
         NA / 0
         0,91 [0,66;1,26]

    Cardiovascular death

    NA / 719
         NA / 0
         0,78 [0,50;1,22]

    All cause death

    NA / 719
         NA / 0
         0,79 [0,54;1,15]

    stroke (fatal and non fatal)

    NA / 719
         NA / 0
         0,80 [0,49;1,30]

    myocardial infarction (fatal and non fatal)

    NA / 719
         NA / 0
         classic 1,31 [0,78;2,20]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.

    Meta-analysis of all similar trials:

    anti hypertensive agent in diabetes for type1 and 2 diabetic patients with hypertension

    anti hypertensive agent in hypertension for diabetic patients



    Reference(s)

    Trials register # NA
    • Lindholm LH, Hansson L, Ekbom T, Dahl�f B, Lanke J, Linjer E, Scherst�n B, Wester PO, Hedner T, de Faire U. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.. J Hypertens 2000;18:1671-5
      Pubmed | Hubmed | Fulltext
    • Hansson L, Lindholm LH, Ekbom T, Dahl�f B, Lanke J, Scherst�n B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.. Lancet 1999;354:1751-6
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend